Highlights in Multiple Myeloma from the 2016 ASCO Annual Meeting
Release Date: June 24, 2016
Expiration Date: June 24, 2017
Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.
The American Society of Clinical Oncology (ASCO) 2016 annual meeting highlights for multiple myeloma covers the most exciting and clinically relevant data presented at the conference. A group of expert faculty, including Dr. Sagar Lonial, Dr. Philippe Moreau, Dr. Robert Z. Orlowski, Dr. Joshua Richter, and Dr. Edward A. Stadtmauer, provide overviews of data spanning topics such as evolving treatment strategies, real-world data, updates to existing therapies and novel agents under investigation, while sharing insights into the impact of these data on clinical practice.
This activity is designed for physicians, pharmacists, physician assistants, nurses, and other health care professionals who have an interest in enhancing their clinical skills in multiple myeloma.
Upon completion of this educational activity, participants should be able to:
- Evaluate the most significant findings from clinical trials in multiple myeloma as presented at national and international hematology/oncology conferences in 2016
- Describe how emerging data about diagnosis, assessment, and treatment of multiple myeloma are relevant to practicing clinicians, and how this data may be incorporated into clinical practice
Immunotherapy, PROs and Prognostication with PET – Sagar Lonial, MD
The Role of Transplant and Doublet vs. Triplet Salvage Therapy – Philippe Moreau, MD
Smoldering Myeloma, Outcomes Predictors, and Checkpoint Inhibitors – Robert Z. Orlowski, MD, PhD
Novel Drugs, Conditioning Regimens, and Induction Therapy – Joshua Richter, MD
Next-Generation Proteasome Inhibitors, MRD and Genetic Plasma Cell Signatures – Edward A. Stadtmauer, MD
Instructions for Participation and Credit
This activity is eligible for credit through June 24, 2017. After this date, this activity will expire and no further credit will be awarded.
1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates for CME and CNE credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Sagar Lonial, MD
Vice Chair of Clinical Affairs
Department of Hematology and Medical Oncology
Winship Cancer Institute
Emory University School of Medicine
Dr. Sagar Lonial earned his medical degree from the University of Louisville School of Medicine. He completed his internship and residency at Baylor College of Medicine in Houston, Texas, followed by a fellowship in hematology/oncology at Emory University School of Medicine in Atlanta, Georgia. He is the Department Chair for Hematology and Medical Oncology at Emory University.
Dr. Lonial serves as Vice Chair of the Myeloma Committee in the Eastern Cooperative Oncology Group and as Chair of the Steering Committee for the Multiple Myeloma Research Consortium. Additionally, he is on the Board of Directors for the International Myeloma Society and on the Scientific Advisory Board for the International Myeloma Foundation. Dr. Lonial is the myeloma editor for Clinical Lymphoma and Myeloma and is on the editorial board for the Journal of Clinical Oncology. He is also an ad hoc reviewer for Blood, Cancer Research, Clinical Cancer Research, Haematologica, Leukemia, and other journals, and has authored or co-authored over 200 papers and abstracts.
Dr. Lonial has worked in the field of immunotherapy and cancer, and has spent time developing the B-cell malignancy program with respect to novel targeted agents in laboratory models as well as early clinical trials. His previous laboratory work has focused on evaluating the impact of purified dendritic cell subsets on the nature of immune responses against antigen. Most recently, Dr. Lonial has focused on combinations of novel agents as therapy for myeloma and lymphoma, particularly evaluating combinations that may result in synergistic inhibition of the PI3-K/Akt pathway and the role of 14-3-3 in proteasome function.
Philippe Moreau, MD
University Professor of Clinical Hematology
Nantes Faculty of Medicine
University Hospital of Nantes
Dr. Philippe Moreau is head of the Hematology Department at the University Hospital of Nantes, France. He specializes in clinical hematology, with a particular focus on multiple myeloma and its treatment with high-dose therapy and novel agents. Dr. Moreau was appointed University Professor of Clinical Hematology at Nantes Faculty of Medicine in 2003.
As leading researcher in multiple myeloma, Dr. Moreau is head of the unit for early phase 1 and phase 2 trials in clinical hematology at the University Hospital of Nantes. Additionally, he was a member of the organizing committee for the 2011 International Myeloma Workshop in Paris. Dr. Moreau is currently a member of the administration council of the Intergroupe Francophone du Myélome (IFM), and he was chairman from 2006 through 2009.
Dr. Moreau is widely published, with more than 300 per-reviewed articles and reviews that have appeared in high impact factor journals including The New England Journal of Medicine, Journal of Clinical Oncology, Lancet Oncology, and Blood. In addition, he is a member of the editorial board of the Journal of Clinical Oncology, Blood, and Blood Cancer Journal and is a frequently invited speaker at international hematologic oncology meetings.
Robert Z. Orlowski, MD, PhD
Professor, Chair Ad Interim
Department of Lymphoma/Myeloma
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Dr. Robert Orlowski earned his doctoral degree in molecular biophysics and biochemistry from Yale University and his medical degree from the Yale University School of Medicine. He completed his internship and residency in internal medicine at Barnes Hospital at Washington University, St. Louis School of Medicine. Dr. Orlowski is a professor and Chair Ad Interim in the Department of Lymphoma/Myeloma, and professor in the Department of Experimental Therapeutics, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.
Board-certified in internal medicine and medical oncology, Dr. Orlowski has published numerous book chapters, articles, and abstracts on cancer therapy with a focus on the pathogenesis of oncologic disease and mechanisms of action of chemotherapeutics. In addition, he is a reviewer for several journals, including Blood, Cancer Research, Journal of Clinical Oncology, and The New England Journal of Medicine. His clinical research efforts focus on novel clinical trials for patients with hematologic malignancies.
Joshua Richter, MD
Clinical Assistant Professor at Rutgers
Division of Myeloma John Theurer Cancer Center
Hackensack University Medical Center
Hackensack, New Jersey
Dr. Joshua Richter received his medical degree from New York Medical College. He completed a multiple myeloma residency at St. Vincent’s Hospital – New York Medical College, and a hematology/oncology fellowship at Yale Cancer Center, Yale University. Dr. Richter is a Clinical Assistant Professor at Rutgers and works in the Division of Myeloma at the John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey.
Dr. Richter is board certified in internal medicine, hematology, and medical oncology. He has been published in numerous oncology journals, including Blood, Clinical Immunology, and Leukemia Lymphoma. Dr. Richter has worked at some of the world’s most prestigious cancer centers and specializes in multiple myeloma at John Theurer Cancer Center which allows the division to further expand its internationally-recognized myeloma clinical and research practice.
Edward A. Stadtmauer, MD
Chief, Hematologic Malignancies
Abramson Cancer Center
University of Pennsylvania
Dr. Edward Stadtmauer completed his medical degree at the University of Pennsylvania School of Medicine, and served his internship and residency in internal medicine at Albert Einstein College of Medicine, Bronx, New York. He completed his fellowship in hematology-oncology at the University of Pennsylvania where he is currently chief of the Hematologic Malignancies Section of the Abramson Cancer Center.
Board certified in internal medicine, hematology, and medical oncology, Dr. Stadtmauer is a reviewer for numerous journals and is on the editorial board of the Journal of Clinical Oncology. He is widely published on the subjects of acute and chronic leukemia, autologous bone marrow transplantation, and multiple myeloma. Dr. Stadtmauer’s writings have appeared in peer-reviewed journals such as Annals of Internal Medicine, Blood, Bone Marrow Transplantation, Journal of Clinical Oncology, and The New England Journal of Medicine, among others.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-16-102-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: Program Number: 16-102-030
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Sagar Lonial has received honoraria as a consultant from Bristol-Myers Squibb Company, Celgene Corporation, Janssen Pharmaceuticals, Inc., Novartis AG, Onyx, and Takeda Oncology.
Dr. Philippe Moreau has received honoraria related to formal advisory activities from Bristol-Myers Squibb Company, Celgene Corporation, Janssen Pharmaceuticals, Inc., Novartis AG, and Takeda Oncology.
Dr. Robert Orlowski has received honoraria related to formal advisory activities from Array BioPharma, Bristol-Myers Squibb Company, Celgene Corporation, FORMA Therapeutics, Inc., Janssen Pharmaceuticals, Inc., Takeda Oncology, and Onyx. He has received grant support related to research activities from Array BioPharma, Bristol-Myers Squibb, Celgene, Spectrum Pharmaceuticals, Inc., Takeda Oncology, and Onyx.
Dr. Joshua Richter has received honoraria related to speakers’ bureau activities from Amgen Inc., Celgene Corporation, Janssen Pharmaceuticals, Inc., Novartis AG, and Takeda Oncology, as well as consultant fees from Amgen and Takeda Oncology.
Dr. Edward Stadtmauer has received honoraria as a consultant from Novartis AG, Onyx, Sanofi, and Takeda Oncology. He has received grant support related to research activities from Celgene Corporation, Novartis, and Onyx.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, and Patrick Brooks, PharmD, Medical Director, Oncology, have has no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
Off-Label Disclosures/Investigational Disclosures
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Drs. Orlowski, Richter, and Stadtmauer have indicated that they do intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Drs. Lonial and Moreau have indicated that they do not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Drs. Moreau, Orlowski, Richter, and Stadtmauer have indicated that they do intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.
Dr. Lonial has indicated that he does not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.
MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen Inc., Celgene Corporation, and Takeda Oncology.
©2016 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.